WO2004087676A1 - Verfahren zur herstellung von telmisartan - Google Patents
Verfahren zur herstellung von telmisartan Download PDFInfo
- Publication number
- WO2004087676A1 WO2004087676A1 PCT/EP2004/003217 EP2004003217W WO2004087676A1 WO 2004087676 A1 WO2004087676 A1 WO 2004087676A1 EP 2004003217 W EP2004003217 W EP 2004003217W WO 2004087676 A1 WO2004087676 A1 WO 2004087676A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvent
- acid
- water
- tert
- potassium
- Prior art date
Links
- ILXRSCZVHSZGCS-UHFFFAOYSA-N CCCc([nH]c1c2)nc1c(C)cc2-c1nc2ccccc2[n]1C Chemical compound CCCc([nH]c1c2)nc1c(C)cc2-c1nc2ccccc2[n]1C ILXRSCZVHSZGCS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
Definitions
- the present invention is a novel process for the preparation of 4 '- [2-n-propyl-4-methyl-6- (1-methylbenzimidazol-2-yl) benzimidazol-1-ylmethyl] biphenyl-2-ylmethyl.
- carboxylic acid INN: telmisartan
- Telmisartan is an angiotensin II receptor antagonist useful in the treatment of hypertension and other medical indications as described in EP 502314 B1.
- the active substance has the following structure:
- Telmisartan is generally produced and sold in the form of the free acid. As disclosed in WO 00/43370, crystalline telmisartan is present in two polymorphic forms having different melting points. Under the influence of heat and moisture, the lower-melting polymorphic form B irreversibly changes to the higher-melting polymorphic form A.
- telmisartan The technical synthesis of telmisartan has hitherto been carried out by reacting 2-n-propyl-4-methyl-6- (1'-methylbenzimidazol-2 , -yl) -benzimidazole (I) with 4'-bromomethyl-biphenyl-2-carboxylic acid tert-butyl ester (II) and subsequent saponification according to the following scheme 1.
- Scheme 1 :
- the precipitating product in the form of long needles as a solid can be difficult to filter, wash and isolate, also characterized by the inclusion of solvent by a very long drying time and forms the process of drying large, very hard chunks. A crushing of these chunks leads to a dry powder which shows a high tendency to electrostatic charge and is practically not free-flowing.
- Z is a leaving group such as a halogen atom, for example a chlorine, bromine or iodine atom, or a substituted sulphonyloxy group, for example a methanesulphonyloxy, phenylsulphonyloxy or p-toluenesulphonyloxy group, the compound being 2-cyano-4 '- [2 "- n-propyl-4 "-methyl-6" - (1 "-methylbenzimidazol-2" '- yl) benzimidazole-1 "-ylmethyl] biphenyl
- a halogen atom for example a chlorine, bromine or iodine atom
- a substituted sulphonyloxy group for example a methanesulphonyloxy, phenylsulphonyloxy or p-toluenesulphonyloxy group
- step (a) which, if desired, is subjected to work-up (step (a)), and subsequent hydrolysis of the nitrile to the acid function (step (b)) and, if desired, conversion of the compound (V) during the workup into the hydrochloride considerable advantages over that in Scheme 1 shown synthesis, in particular does not have the disadvantages mentioned above for the large-scale production according to the conventional method.
- Dimethylacetamide / tert-butanol, toluene and benzene optionally in the presence an acid-binding agent such as sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium methylate, potassium methoxide, potassium tert-pentoxide, potassium tert-butylate, potassium n-butylate, sodium hydride, triethylamine or pyridine, the latter two also being used as the solvent can, for example, carried out at a temperature between 0 and 100 ° C.
- the base is, if it is a solid, preferably used in pulverized form,
- the reaction of the compound (I) with a compound of the general formula (IV) in a solvent or solvent mixture is selected from dimethylsulfoxide, dimethylformamide, dimethylacetamide, dimethylformamide / tert-butanol and dimethylacetamide / tert-butanol in the presence of sodium hydroxide, potassium hydroxide or potassium tert-butylate at a temperature between 0 and 30 ° C.
- Distilled water-jet vacuum the residue treated with a solvent in which the nitrile (V) is limited or moderately soluble in heat, for example with an alcohol such as methanol, ethanol, n-propanol, i-propanol, n-butanol or i -
- Butanol with an aromatic hydrocarbon such as benzene or toluene, with an ethereal solvent such as diethyl ether, tetrahydrofuran, dioxane or tert.
- aromatic hydrocarbon such as benzene or toluene
- ethereal solvent such as diethyl ether, tetrahydrofuran, dioxane or tert.
- Butyl methyl ether wherein the ethereal solvents and in particular tert.
- Butyl methyl ether are preferred, or with water, which optionally filtered off with suction after cooling to 10 to 20 ° C precipitating crystals and washed first with the solvent used and then with water.
- the product at elevated temperature, for example at 50- 100 ° C, dried in a vacuum oven.
- the nitrile (V) is usually obtained in excellent yields between 80 and 90% of theory and excellent quality (purity after HPLC> 99.5%).
- the subsequent hydrolysis of the nitrile function into a carboxy group is conveniently carried out in water, in an organic solvent or in a mixture of an organic solvent with water, the organic solvent being, for example, methanol, ethanol, n-propanol, isopropanol, tetrahydrofuran, dioxane, Ethylene glycol, propylene glycol, diglyme, dimethyl sulfoxide or diethylene glycol monomethyl ether, in the presence of an acid such as trifluoroacetic acid, trichloroacetic acid, hydrochloric acid, sulfuric acid or phosphoric acid or in the presence of a base such as lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide or calcium hydroxide or their anhydrides at temperatures between 80 and 200 ° C, wherein the water required for the reaction may also be part of one of the reagents used, for example one of the abovementioned aqueous acids, or may be generated from the rea
- the hydrolysis of the nitrile function takes place in a high boiling solvent system selected from ethylene glycol / water and
- Propylene glycol / water in the presence of a base, wherein potassium hydroxide is particularly suitable, at temperatures between 140 and 200 ° C, in particular at a temperature between 155 and 185 ° C.
- the solvent is removed, for example, distilled off in a water-jet vacuum, the residue is diluted with water and taken up with hydrochloric acid, for example with 5 to about 32% (concentrated) hydrochloric acid, preferably with 5 to 20% hydrochloric acid, wherein Telmisartan hydrochloride crystallized out.
- the crystal suspension is adjusted to 10 to Cooled to 25 ° C and for some time, for example, up to 3 hours, stirred at this temperature. After aspirating the crystals is washed with water and, if necessary, in a vacuum oven at elevated temperature, for example at 50 to 120 ° C, dried.
- telmisartan hydrochloride can be released in the usual way telmisartan in the acid form, such as by titration with aqueous alkali hydroxide.
- telmisartan in the acid form such as by titration with aqueous alkali hydroxide.
- the release of the acid form takes place analogously to the process described in WO 0043370 (page 3, line 6 to page 4, line 38, and examples 1 to 3).
- the process according to the invention has, for industrial production, inter alia the following advantages which may be mentioned in particular: compounds of the formula (IV), in particular the 4'-bromomethyl-2-cyanobiphenyl, are prepared industrially and are commercially available at low cost;
- the nitrile (V) is obtained in excellent yields between 80 and 90% of theory and excellent quality (purity after HPLC> 99.5%);
- telmisartan can be isolated either as zwitterion or, preferably, by precipitation with hydrochloric acid as easily filterable and thus easy to clean hydrochloride.
- reaction vessel 50 to 200 ml of solvent, preferably 80 to 120 ml, are introduced per 0.1 mol of the compound (I), the compound (I) is suspended in the solvent and 0.1 to 0.2 mol with stirring , Base, preferably 0.102 to 0.12 mol, added portionwise with stirring, the temperature between 10 and 50 ° C, preferably 15 to 30 C held, and stirred after completion of the exothermic reaction for a further up to 3 hours at this temperature can.
- the mixture is to about 0 -, cooled to -10 C C., for example about 5 ° C and then a mixture of 0.1 to 0.2 mol of a compound of the general formula (IV), preferably 0.100 to 0.12 mol, with 50 to 200 ml of solvent (per 0.1 mol of compound (IV)) at 10 to 30 ° C, preferably at about 20 ° C added dropwise.
- the reaction mixture is kept at about 0-20 ° C., preferably 5-10 ° C., by cooling with ice bath. Afterwards it is possible to rinse with a few ml of solvent and subsequently to stir for up to 3 hours at 0-20 ° C.
- the base in 30 to 100 ml of solvent, preferably dimethylformamide, dimethylacetamide, dimethylformamide / tert-butanol or dimethylacetamide / tert-butanol, initially charged at 10 to 30 ° C, for example about 20 ° C to a Stirred and then added slowly a suspension of the compound (I) in 30 to 100 ml of solvent at this temperature. All further steps correspond to those of the preceding embodiment.
- the solvent is expediently distilled off to a considerable extent under reduced pressure, for example in a water-jet vacuum, the product crystallizing out.
- After cooling the residue to about 40 to 80 ° C, preferably about 60 ° C, with 100 to 300 ml of solvent (per 0.1 mol batch size, based on compound (I)), preferably tert. Butyl methyl ether, diluted and stirred for up to 5 hours without energy.
- the mixture is cooled to 0 to 30 ° C, preferably 15 - 20 ° C, and stirred again for up to 5 hours at this temperature.
- the crystals are filtered off with suction, washed in portions with 50 to 150 ml of the solvent and then with 200 to 300 ml of water.
- the product is dried in a vacuum oven at 50 to 100 ° C, preferably about 60 ° C.
- 0.361 mol of the nitrile (V) is initially charged in 1.5 to 2 L of the organic solvent, preferably ethylene glycol, 25 to 50 ml of water and 2.5 to 3 mol of the base are added with stirring for up to 24 Hours at 140 to 200 ° C, preferably at 155 to 185 ° C, heated. All further steps correspond to those of the preceding embodiment.
- the quantities are based on a batch size of 0.05 moles of
- the solvent is expediently removed under reduced pressure, for example distilled off in a water-jet vacuum, the residue with 30 to 100 ml of water, preferably about 5 ml, diluted and in a mixture of 100 to 150 ml of water (preferably about 125 ml) and 40 to 60 ml (preferably about 50 ml) conc.
- Hydrochloric acid (about 32%) stirred, which can be rinsed with a little water.
- the crystallizing Telmisartan hydrochloride is cooled to 10 to 25 ° C and is stirred for up to 3 hours at this temperature. After aspirating the crystals is washed with 50 to 200 ml of water and dried in a vacuum oven at 50 to 120 ° C.
- the solvent is largely distilled off under aspirator vacuum, whereby the product crystallizes out.
- the residue is cooled to 60 ° C, with 225 ml of tert.
- the solvent is largely distilled off under aspirator vacuum, whereby the product crystallizes out.
- the residue is cooled to 60 ° C, with 250 ml of tert. Butyl methyl ether diluted and stirred for 2 hours without energy.
- the crystals are filtered off with suction, with 100 ml of tert. Butyl methyl ether, then washed with 250 ml of water in portions and then dried in a vacuum oven at 80 ° C.
- Example 7 Telmisartan 5.51 g of Telmisartan x HCl are dissolved in 50 ml of 40% acetic acid with refluxing. Then the brown solution is filtered hot over 1, 1 g of charcoal, washed with 2.5 ml of 40% acetic acid and the light brown filtrate added dropwise with stirring at 80 - 90 ° C with 2.5 ml of 4N NaOH. The telmisartan crystallizes out, the suspension is diluted with 30 ml of water and slowly cooled to room temperature. The Telmisartan is filtered off with suction and washed with 50 ml of water. The Telmisartan is dried in a vacuum oven at 80 ° C.
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ543244A NZ543244A (en) | 2003-03-31 | 2004-03-26 | Method for the production of telmisartan (4'-[2-N-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)benzimidazol-1-ylmethyl]biphenyl-2-carboxylic acid) |
CA2520714A CA2520714C (en) | 2003-03-31 | 2004-03-26 | Process for manufacture of telmisartan |
PL04739071T PL1611108T3 (pl) | 2003-03-31 | 2004-03-26 | Sposób wytwarzania telmisartanu |
JP2005518684A JP5160740B2 (ja) | 2003-03-31 | 2004-03-26 | テルミサルタンの製造方法 |
MXPA05009529A MXPA05009529A (es) | 2003-03-31 | 2004-03-26 | Proceso para la fabricacion de telmisartan. |
AU2004226239A AU2004226239B2 (en) | 2003-03-31 | 2004-03-26 | Method for the production of telmisartan |
DK04739071.1T DK1611108T3 (da) | 2003-03-31 | 2004-03-26 | Fremgangsmåde til fremstilling af telmisartan |
KR1020057018333A KR101096499B1 (ko) | 2003-03-31 | 2004-03-26 | 텔미사탄의 제조방법 |
BRPI0408861-1A BRPI0408861A (pt) | 2003-03-31 | 2004-03-26 | processo de fabricação de telmisartan |
AT04739071T ATE515500T1 (de) | 2003-03-31 | 2004-03-26 | Verfahren zur herstellung von telmisartan |
EP04739071A EP1611108B1 (de) | 2003-03-31 | 2004-03-26 | Verfahren zur herstellung von telmisartan |
SI200431740T SI1611108T1 (sl) | 2003-03-31 | 2004-03-26 | Postopek za pripravo telmisartana |
IL171145A IL171145A (en) | 2003-03-31 | 2005-09-28 | Method for the production of telmisartan |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10314702A DE10314702A1 (de) | 2003-03-31 | 2003-03-31 | Verfahren zur Herstellung von Telmisartan |
DEDE10314702.0 | 2003-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004087676A1 true WO2004087676A1 (de) | 2004-10-14 |
Family
ID=33016100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/003217 WO2004087676A1 (de) | 2003-03-31 | 2004-03-26 | Verfahren zur herstellung von telmisartan |
Country Status (26)
Country | Link |
---|---|
US (2) | US7193089B2 (de) |
EP (2) | EP1611108B1 (de) |
JP (1) | JP5160740B2 (de) |
KR (1) | KR101096499B1 (de) |
CN (1) | CN100418953C (de) |
AR (2) | AR043794A1 (de) |
AT (1) | ATE515500T1 (de) |
AU (1) | AU2004226239B2 (de) |
BR (1) | BRPI0408861A (de) |
CA (1) | CA2520714C (de) |
CL (1) | CL2004000687A1 (de) |
CY (2) | CY1112020T1 (de) |
DE (1) | DE10314702A1 (de) |
DK (2) | DK2322511T3 (de) |
ES (2) | ES2369081T3 (de) |
IL (1) | IL171145A (de) |
MX (1) | MXPA05009529A (de) |
NZ (1) | NZ543244A (de) |
PE (1) | PE20050390A1 (de) |
PL (2) | PL2322511T3 (de) |
PT (2) | PT2322511E (de) |
RU (1) | RU2430092C2 (de) |
SI (2) | SI2322511T1 (de) |
TW (1) | TWI335916B (de) |
UY (1) | UY28246A1 (de) |
WO (1) | WO2004087676A1 (de) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108375A1 (en) * | 2004-05-11 | 2005-11-17 | Cipla Limited | Process for the preparation of telmisartan |
EP1719766A3 (de) * | 2005-05-03 | 2006-12-20 | Dipharma S.p.A. | Verfahren zur Herstellung von Telmisartan |
JP2008503595A (ja) * | 2004-10-15 | 2008-02-07 | テバ ファーマシューティカル インダストリーズ リミティド | テルミサルタンの調製方法 |
EP2103588A1 (de) * | 2008-03-20 | 2009-09-23 | Lek Pharmaceuticals D.D. | 2'-Halobiphenyl-4-yl-Zwischenprodukte bei der Synthese von Angiotensin-II-Antagonisten |
EP2103609A1 (de) * | 2008-03-20 | 2009-09-23 | Lek Pharmaceuticals D.D. | Katalysierte Carbonylierung bei der Synthese von Angiotensin-II-Antagonisten |
WO2009116089A2 (en) * | 2008-03-14 | 2009-09-24 | Ipca Laboratories Limited | Novel intermediates and method for synthesis of 4'-[(1,4'-dimethyl-2'-propyl-[2,6'- bi-1hbenzimidazol]-l-yl)methyl]-1,1-biphenyl]-2-carboxylic acid. |
WO2009115585A1 (en) * | 2008-03-20 | 2009-09-24 | Lek Pharmaceuticals D.D. | Catalyzed carbonylation in the synthesis of angiotensin ii antagonists |
EP2123648A1 (de) | 2008-05-20 | 2009-11-25 | Chemo Ibérica, S.A. | Verfahren zur Herstellung von Telmisartan |
EP2149566A1 (de) | 2008-07-15 | 2010-02-03 | Chemo Ibérica, S.A. | Verfahren zur Herstellung von Telmisartan |
WO2010146187A2 (en) | 2009-06-19 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
EP2305650A1 (de) | 2009-09-21 | 2011-04-06 | Chemo Ibérica, S.A. | Neuartiges Verfahren zur Herstellung von Telmisartan |
US7943781B2 (en) | 2004-10-18 | 2011-05-17 | Dr. Reddy's Laboratories Limited | Process for preparing telmisartan |
WO2012055941A1 (en) | 2010-10-27 | 2012-05-03 | Krka,Tovarna Zdravil, D. D., Novo Mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10314702A1 (de) * | 2003-03-31 | 2004-10-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von Telmisartan |
DE102004045796A1 (de) * | 2004-09-22 | 2006-03-23 | Merck Patent Gmbh | Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung |
US7968727B2 (en) | 2005-04-01 | 2011-06-28 | Lek Pharmaceuticals, D.D. | Synthesis of 4-bromomethyl-2′-formylbiphenyl and 4-bromomethyl-2′-hydroxymethylbiphenyl and its use in preparation of angiotensin II antagonists |
WO2006136916A2 (en) * | 2005-06-20 | 2006-12-28 | Glenmark Pharmaceuticals Limited | Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same |
US20060264491A1 (en) * | 2006-06-08 | 2006-11-23 | Chemagis Ltd. | Telmisartan production process |
CN101172968B (zh) * | 2006-11-01 | 2010-05-12 | 浙江天宇药业有限公司 | 2-正丙基-4甲基-6-(甲基苯并咪唑-2-基)苯并咪唑盐及其制备方法 |
EP2170835A1 (de) * | 2007-07-03 | 2010-04-07 | Krka Tovarna Zdravil, D.D., Novo Mesto | Verfahren zur herstellung von telmisartan |
CZ302272B6 (cs) | 2007-07-09 | 2011-01-19 | Zentiva, A. S. | Zpusob výroby 4´-[[4-methyl-6-(1-methyl-1H-benzimidazol-2-yl)-2-propyl-1H-benzimidazol-1-yl]methyl]biphenyl-2-karboxylové kyseliny (telmisartanu) |
EP2277866A1 (de) | 2009-06-22 | 2011-01-26 | Inke, S.A. | Verfahren zur Herstellung von Telmisartan |
CN102267949A (zh) * | 2011-06-14 | 2011-12-07 | 张长利 | 替米沙坦制备新工艺 |
WO2014027280A1 (en) | 2012-08-14 | 2014-02-20 | U Amarnath Amarnath | One pot process for the preparation of telmisartan |
CN103787982A (zh) * | 2012-10-31 | 2014-05-14 | 上海特化医药科技有限公司 | 制备替米沙坦的方法及其中间体 |
CN104557724B (zh) * | 2014-11-17 | 2017-01-11 | 江苏中邦制药有限公司 | 替米沙坦不定形晶型及其制备方法 |
CN105130905B (zh) * | 2015-09-17 | 2017-09-08 | 浙江金立源药业有限公司 | 一种替米沙坦的合成方法 |
CN109912512B (zh) * | 2017-12-13 | 2023-05-30 | 上海科胜药物研发有限公司 | 一种新的替米沙坦杂质化合物及其制备方法和用途 |
CN112251770B (zh) * | 2020-10-14 | 2021-07-27 | 湖南大学 | 一种抗高血压药替米沙坦中间体电化学制备新方法 |
CN113307775B (zh) * | 2021-04-16 | 2022-04-22 | 河北戴桥医药科技有限公司 | 一种替米沙坦的制备方法 |
WO2023204729A1 (ru) * | 2022-04-19 | 2023-10-26 | Общество с ограниченной ответственностью "Гелеспон" | Фармацевтические композиции на основе новой субстанции 4-[2-(1н-имидазол-4-ил)-этилкарбамоил]-бутановой кислоты и способ получения субстанции |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0502314A1 (de) * | 1991-02-06 | 1992-09-09 | Dr. Karl Thomae GmbH | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU1836357C (ru) * | 1990-07-23 | 1993-08-23 | Др.Карл Томэ ГмбХ | Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами |
DE4023369A1 (de) * | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
DE4103492A1 (de) * | 1991-02-06 | 1992-10-08 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
US5614519A (en) | 1991-02-06 | 1997-03-25 | Karl Thomae Gmbh | (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists |
US6358986B1 (en) | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
DE19901921C2 (de) * | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
US6737432B2 (en) | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
DE10314702A1 (de) * | 2003-03-31 | 2004-10-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von Telmisartan |
-
2003
- 2003-03-31 DE DE10314702A patent/DE10314702A1/de not_active Withdrawn
-
2004
- 2004-03-17 US US10/802,142 patent/US7193089B2/en active Active
- 2004-03-26 EP EP04739071A patent/EP1611108B1/de not_active Expired - Lifetime
- 2004-03-26 PT PT101925618T patent/PT2322511E/pt unknown
- 2004-03-26 CN CNB2004800087194A patent/CN100418953C/zh not_active Expired - Lifetime
- 2004-03-26 JP JP2005518684A patent/JP5160740B2/ja not_active Expired - Lifetime
- 2004-03-26 MX MXPA05009529A patent/MXPA05009529A/es active IP Right Grant
- 2004-03-26 SI SI200432083T patent/SI2322511T1/sl unknown
- 2004-03-26 PT PT04739071T patent/PT1611108E/pt unknown
- 2004-03-26 AT AT04739071T patent/ATE515500T1/de active
- 2004-03-26 AU AU2004226239A patent/AU2004226239B2/en not_active Expired
- 2004-03-26 DK DK10192561.8T patent/DK2322511T3/da active
- 2004-03-26 PL PL10192561T patent/PL2322511T3/pl unknown
- 2004-03-26 ES ES04739071T patent/ES2369081T3/es not_active Expired - Lifetime
- 2004-03-26 EP EP10192561.8A patent/EP2322511B1/de not_active Expired - Lifetime
- 2004-03-26 SI SI200431740T patent/SI1611108T1/sl unknown
- 2004-03-26 RU RU2005133479/04A patent/RU2430092C2/ru active
- 2004-03-26 WO PCT/EP2004/003217 patent/WO2004087676A1/de active Application Filing
- 2004-03-26 PL PL04739071T patent/PL1611108T3/pl unknown
- 2004-03-26 KR KR1020057018333A patent/KR101096499B1/ko active IP Right Grant
- 2004-03-26 DK DK04739071.1T patent/DK1611108T3/da active
- 2004-03-26 NZ NZ543244A patent/NZ543244A/en unknown
- 2004-03-26 ES ES10192561T patent/ES2432647T3/es not_active Expired - Lifetime
- 2004-03-26 BR BRPI0408861-1A patent/BRPI0408861A/pt not_active Application Discontinuation
- 2004-03-26 CA CA2520714A patent/CA2520714C/en not_active Expired - Fee Related
- 2004-03-29 UY UY28246A patent/UY28246A1/es not_active Application Discontinuation
- 2004-03-29 TW TW093108537A patent/TWI335916B/zh active
- 2004-03-29 PE PE2004000331A patent/PE20050390A1/es not_active Application Discontinuation
- 2004-03-30 CL CL200400687A patent/CL2004000687A1/es unknown
- 2004-03-31 AR ARP040101066A patent/AR043794A1/es active IP Right Grant
-
2005
- 2005-09-28 IL IL171145A patent/IL171145A/en active IP Right Grant
-
2011
- 2011-09-28 CY CY20111100938T patent/CY1112020T1/el unknown
-
2012
- 2012-07-17 AR ARP120102582A patent/AR087209A2/es unknown
-
2013
- 2013-01-25 US US13/750,551 patent/US8993778B2/en active Active
- 2013-10-09 CY CY20131100879T patent/CY1115156T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0502314A1 (de) * | 1991-02-06 | 1992-09-09 | Dr. Karl Thomae GmbH | Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
Non-Patent Citations (2)
Title |
---|
COTTINEAU B ET AL.: "Synthesis and Hypogylcemic Evaluation of Substituted Pyrazole-4-Carboxylic Acids", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 12, 2002, pages 2105 - 2108, XP002280950 * |
MEDERSKI ET AL: "Non-Peptide Angiotensin II Receptor Antagonists: Synthesis and Biological Activity of a Series of Novel 4,5-Dihydro-4-oxo-3H-imidazo [4,5-c]pyridine Derivatives", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 11, 1994, pages 1632 - 1645, XP002129108, ISSN: 0022-2623 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005108375A1 (en) * | 2004-05-11 | 2005-11-17 | Cipla Limited | Process for the preparation of telmisartan |
US8691999B2 (en) | 2004-05-11 | 2014-04-08 | Cipla Limited | Process for the preparation of telmisartan |
JP2008503595A (ja) * | 2004-10-15 | 2008-02-07 | テバ ファーマシューティカル インダストリーズ リミティド | テルミサルタンの調製方法 |
US7943781B2 (en) | 2004-10-18 | 2011-05-17 | Dr. Reddy's Laboratories Limited | Process for preparing telmisartan |
EP1719766A3 (de) * | 2005-05-03 | 2006-12-20 | Dipharma S.p.A. | Verfahren zur Herstellung von Telmisartan |
WO2009116089A3 (en) * | 2008-03-14 | 2010-11-25 | Ipca Laboratories Limited | Novel intermediates and method for synthesis of 4'-[(1,4'-dimethyl-2'-propyl-[2,6'- bi-1hbenzimidazol]-l-yl)methyl]-1,1-biphenyl]-2-carboxylic acid. |
WO2009116089A2 (en) * | 2008-03-14 | 2009-09-24 | Ipca Laboratories Limited | Novel intermediates and method for synthesis of 4'-[(1,4'-dimethyl-2'-propyl-[2,6'- bi-1hbenzimidazol]-l-yl)methyl]-1,1-biphenyl]-2-carboxylic acid. |
EP2103588A1 (de) * | 2008-03-20 | 2009-09-23 | Lek Pharmaceuticals D.D. | 2'-Halobiphenyl-4-yl-Zwischenprodukte bei der Synthese von Angiotensin-II-Antagonisten |
WO2009115584A3 (en) * | 2008-03-20 | 2009-11-12 | Lek Pharmaceuticals D.D. | 2'-halobiphenyl-4-yl intermediates in the synthesis of angiotensin ii antagonists |
WO2009115585A1 (en) * | 2008-03-20 | 2009-09-24 | Lek Pharmaceuticals D.D. | Catalyzed carbonylation in the synthesis of angiotensin ii antagonists |
EP2103609A1 (de) * | 2008-03-20 | 2009-09-23 | Lek Pharmaceuticals D.D. | Katalysierte Carbonylierung bei der Synthese von Angiotensin-II-Antagonisten |
US8445693B2 (en) | 2008-03-20 | 2013-05-21 | Lek Pharmaceuticals D.D. | Catalyzed carbonylation in the synthesis of angiotensin II antagonists |
US8410285B2 (en) | 2008-03-20 | 2013-04-02 | Lek Pharmaceuticals D.D. | 2′-halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists |
EP2123648A1 (de) | 2008-05-20 | 2009-11-25 | Chemo Ibérica, S.A. | Verfahren zur Herstellung von Telmisartan |
EP2149566A1 (de) | 2008-07-15 | 2010-02-03 | Chemo Ibérica, S.A. | Verfahren zur Herstellung von Telmisartan |
WO2010146187A3 (en) * | 2009-06-19 | 2011-02-24 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
WO2010146187A2 (en) | 2009-06-19 | 2010-12-23 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Process for the preparation of telmisartan |
EP2305650A1 (de) | 2009-09-21 | 2011-04-06 | Chemo Ibérica, S.A. | Neuartiges Verfahren zur Herstellung von Telmisartan |
WO2012055941A1 (en) | 2010-10-27 | 2012-05-03 | Krka,Tovarna Zdravil, D. D., Novo Mesto | Multilayer pharmaceutical composition comprising telmisartan and amlodipine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1611108B1 (de) | Verfahren zur herstellung von telmisartan | |
DE19901921C2 (de) | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels | |
EP1956018A1 (de) | Verfahren zur Herstellung eines Benzimidazolderivats | |
EP1470111B1 (de) | Verfahren zur herstellung und reinigung von 1,7'-dimethyl-2'-propyl-2,5'-bi-1h-benzimidazol | |
DE102005031348B4 (de) | Verfahren zur Herstellung von 3,4-Dichlorisothiazolcarbonsäure | |
WO2001058903A1 (de) | Verfahren zur herstellung von 2-chlor-benzimidazol-derivaten | |
EP2729444B1 (de) | Verfahren zur herstellung von 2-amino-5-cyano-n,3-dimethylbenzamid | |
EP0083729B1 (de) | Substituierte 1-Benzoyl-2-phenylimino-imidazolidine, deren Säureadditionssalze, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel | |
EP1252159B1 (de) | Verfahren zur herstellung von heterocyclischen verbindungen | |
EP1268400B1 (de) | Verfahren zur herstellung von n-butyryl-4-amino-3-methyl-benzoesäuremethylester und die neue verbindung n-(4-brom-2-methylphenyl)-butanamid | |
EP3935044B1 (de) | Verfahren zur herstellung von 4-amino-5-methylpyridon | |
EP0358044B1 (de) | Verfahren zum Fällen von Cytosin aus alkalischen Lösungen mit Schwefelsäure | |
DE2406972B2 (de) | Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren | |
EP1296962A1 (de) | Verfahren zur herstellung von substituierten 5-amino-n-phenyl-1,2,4-triazol-3-sulfonamiden | |
EP1115683A1 (de) | Verfahren zur drucklosen herstellung von alpha, alpha-dimethylphenylessigsäure aus alpha, alpha-dimethylbenzylcyanid | |
DE10332684B3 (de) | Verfahren zur Herstellung von Bifonazol | |
DE102006059314A1 (de) | Verfahren zur Herstellung von [4-({3,3-Dimethyl-5-[4-(trifluormethyl)-phenyl]-2,3-dihydro-1H-indol-1-yl}sulfonyl)-2-methylphenoxy]essigsäure | |
ZA200506290B (en) | MEthod for the production of telmisartan | |
WO2011110597A1 (de) | Verfahren zur herstellung von strontiumranelat | |
DD247218A1 (de) | Verfahren zur herstellung von 1-substituierten 3-(1-carboxy-1-methyl-ethoxy)-1,6-dihydro-pyridazin-6-onen | |
EP0436088A1 (de) | Verfahren zur Herstellung von 3-Aminopyrazin-2-carbonsäure und den entsprechenden Alkalisalzen | |
DD296072A5 (de) | Verfahren zur herstellung von neuen 1,1'-disubstituierten alpha, alpha'-bis-[pyrazolyloxy-(3)]essigsaeuren und deren salzen | |
DD234574A3 (de) | Verfahren zur herstellung von 3-amino-5-(pyrid-4-yl)-1,2-dihydro-pyrid-2-on |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004739071 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005/06290 Country of ref document: ZA Ref document number: 200506290 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2005/009529 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4162/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2520714 Country of ref document: CA Ref document number: 171145 Country of ref document: IL Ref document number: 1020057018333 Country of ref document: KR Ref document number: 1-2005-501746 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005518684 Country of ref document: JP Ref document number: 20048087194 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004226239 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 543244 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005133479 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2004226239 Country of ref document: AU Date of ref document: 20040326 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004226239 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057018333 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004739071 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0408861 Country of ref document: BR |